Company Overview and News
Sept 11 (Reuters) - Canada’s main stock index touched over three-month lows on Tuesday led by declines in materials companies amid the ongoing Sino-U.S. trade dispute and uncertainty over the future of NAFTA trade pact.
FR OMI IMO ABX OMI ACBFF NPIFF IMO SU NPI OROXF RNX RNX.WT ACB RNKLF CNQ BRPIF FQVLF AG FQM ABX SU
Brookfield Renewable (BEP) (TSX:BEP.UN) posted a weak Q2 2018 result mainly primarily due to weak hydro generation in North America. This weak result does not alter our long-term view of the company. Instead, we believe investors should consider the quality of its business. The company should be able to continue to grow its funds from operations thanks to its inflation-protected power purchase agreements, cost-saving initiatives, and the potential to re-contract its PPAs at higher prices.
TORONTO, July 19, 2018 (GLOBE NEWSWIRE) -- Northland Power Inc. ("Northland") (TSX:NPI) announced today that the Deutsche Bucht Mono Bucket pilot demonstrator ("Demo") project has reached financial close. All required funds for the Demo project have been contributed by Northland and committed by the project lenders.
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
BAMGF H BRLXF NPIFF BAMKF HRNNF BAM TERP NPI
Innergex Renewable Energy (OTCPK:INGXF) (TSX:INE) is a Canada-based renewable power producer with a focus on hydroelectric, wind power and solar photovoltaic projects. The company is currently trading at a premium valuation to its peers. Its valuation is supported by its growth potential, long weighted-average PPA duration, and low maintenance expenditure. However, its debt load is quite high and rising benchmark bond yield can impact its share price.
RNW INE AXY NPIFF MGMXF INGXF MGMXD TRSWF TTM AQN NPI
TORONTO, July 09, 2018 (GLOBE NEWSWIRE) -- Northland Power Inc. (“Northland”) (TSX:NPI) announced it will release its 2018 second quarter financial results after market close on August 8, 2018. Northland management will hold an investor conference call at 10:00 a.m. Eastern Time (ET) on Thursday, August 9, 2018, followed by a question and answer period.
Not for distribution to U.S. newswire services or for dissemination in the United States or its possessions. Any failure to comply with this restriction may constitute a violation of U.S. securities law.
TORONTO, June 22, 2018 (GLOBE NEWSWIRE) -- Northland Power Inc. (“Northland”) (TSX:NPI) today announced that the Taiwan Bureau of Energy (“BOE”) has awarded 232 megawatts (“MW”) to the Hai Long 2 offshore wind farm (“Hai Long 2”) and 512 MW to the Hai Long 3 offshore wind farm (“Hai Long 3”) under Taiwan’s offshore wind auction program. These awards are separate from and in addition to the 300 MW in 2024 that Hai Long 2 was allocated by the Taiwan BOE on April 30, 2018 under Taiwan’s Feed-in-Tariff (“FIT”) program.
Heightened geopolitical tensions in the Taiwan Strait, the narrow sea channel between Taiwan and mainland China that has become an offshore wind farms investment hotspot, has raised concerns on the adequacy of insurance coverage for the sector, according to an insurer focused on renewable energy.
16h - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
16h - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
18h - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
as of ET